Loxo Oncology Announces Pricing of Initial Public Offering

STAMFORD, Conn.Aug. 1, 2014 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced the pricing of its initial public offering of 5,261,538 shares of its common stock at a price to the public of $13.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on August 1, 2014 under the symbol "LOXO." In addition, Loxo Oncology has granted the underwriters a 30-day option to purchase up to 789,230 additional shares of common stock from Loxo Oncology at the same price to cover over-allotments, if any. Concurrently with the offering, the Company is also selling through a private placement 230,769 shares of its common stock to New Enterprise Associates14, L.P., an existing stockholder, at the initial public offering price.

Cowen and Company, LLC and Stifel are acting as joint book-running managers for the offering. JMP Securities LLC and Oppenheimer & Co. Inc. are acting as co-managers.

A registration statement relating to the securities to be sold in the offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on July 31, 2014.

The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island AvenueEdgewood, NY 11717, by telephone at (631) 274-2806 or by fax at (631) 254-7140; or from Stifel, Nicolaus & Company, Inc., Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Jacob S. Van Naarden
         Vice President, Corporate Development and Strategy
         [email protected]

         Peter Rahmer
         The Trout Group, LLC
         [email protected]